Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 84 | ETA2022 | Next issue

44th Annual Meeting of the European Thyroid Association (ETA) 2022

Brussels, Belgium
10 Sep 2022 - 13 Sep 2022

Card image cap

Poster Presentations

Graves’ Disease 1

ea0084ps2-07-57 | Graves’ Disease 1 | ETA2022

Post-alemtuzumab graves’ disease remitting after switch to ocrelizumab

Popescu Veronica , Beirinckx Annemie , Decallonne Brigitte

Objectives: Graves’ hyperthyroidism is a frequent complication of alemtuzumab treatment in MS. We present the case of an MS patient who developed clinically and biochemically overt alemtuzumab-induced Graves’ disease, remitting 6 months after treatment with ocrelizumab and methylprednisolone pulse-therapy.Methods: A 49-year-old man diagnosed with active multiple sclerosis who had undergone alemtuzumab treatment, and developed Graves’ hyper...

ea0084ps2-07-58 | Graves’ Disease 1 | ETA2022

High IGG4 serum levels in graves’ disease compared with nonautoimmune hyperthyroidism

Comi Simone , Lanzolla Giulia , Giudetti Matilde , Menconi Francesca , Marcocci Claudio , Marino Michele

Objectives: A role of IgG4 in Graves’ disease (GD) has been proposed, although the available data are conflicting. In addition, an association between Graves’ orbitopathy (GO) and IgG4-related disease has been postulated, but no firm demonstration has been obtained. Thus, the aim of the present study was to investigate the role of IgG4 in GD.Methods: We performed a cross-sectional investigation in 351 consecutive patients (F=284, M=67; age 48.2...

ea0084ps2-07-59 | Graves’ Disease 1 | ETA2022

TPO antibody status prior to first radioactive iodine therapy as a predictive parameter for early hypothyroidism in graves’ disease

Verdickt Sebastien , Van Nes Falco , Moyson Carolien , Maes Toon , Van Crombrugge Paul , Van den Bruel Annick , Decallonne Brigitte

Introduction: Several studies identified pre-treatment parameters that could help in the prediction of the thyroid functional outcome after radioactive iodine therapy (RAI) in Graves’ disease. However, the role of the thyroid peroxidase antibody (TPO Ab) status is not well studied.Objectives: We investigated if a positive TPO Ab status before radioactive iodine (RAI) therapy in patients with Graves’ hyperthyroidism is a predictive factor for de...

ea0084ps2-07-60 | Graves’ Disease 1 | ETA2022

Polymorphisms in proinflammatory cytokines’ genes and lipid profile in patients with graves’ disease

Neves Celestino , Sergio Neves Joao , Goncalves Juliana , Soares Paula , Delgado Luis , Carvalho Davide

Objective: Graves’ Disease (GD) is one of the most common autoimmune disorders. Some SNP in pro-inflammatory cytokines have already been linked to an increased susceptibility of developing GD. Thyroid hormones are crucial modulators of lipid metabolism. A pro-inflammatory state, may contribute several metabolic changes, including disturbances in lipid metabolism. Our aim was to evaluate if SNP in pro-inflammatory cytokines also contribute to disturbances of lipid profile ...

ea0084ps2-07-61 | Graves’ Disease 1 | ETA2022

Management of graves’ disease among endocrinologists in russia

Khruleva Yulia , Pesheva Ekaterina , Deunezhewa Salima , Morgunova Tatyana , Sytch Yulia

Objective: We aim of the study was to investigate the clinical approach to Graves’ disease (GD) treatment among endocrinologists in Russia.Materials and methods: An online questionnaire survey was conducted among doctors from Sept till Dec 2021. The questions covered the principles of diagnosis, treatment and dynamic observation of adults with GD.Results: 104 endocrinologists participated in the study. 99% of respondents chose...

ea0084ps2-07-62 | Graves’ Disease 1 | ETA2022

Multifocality in sporadic and familiar medullary thyroid cancer: analysis of prevalence and possible predictive roles

Cappagli Virginia , Bottici Valeria , Agate Laura , Molinaro Eleonora , Torregrossa Liborio , Elisei Rossella

Aims: Surgery is the only curative treatment for medullary thyroid cancer (MTC) patients and the gold standard practice is still represented by total thyroidectomy and prophylactic central neck compartment lymphnode dissection. As it happened for differentiated thyroid cancer, in the last years some authors proposed less aggressive and extent surgical modality as hemithyroidectomy and ipsilateral neck compartment dissection in unilateral and solitary sporadic MTC cases. Few st...

ea0084ps2-07-63 | Graves’ Disease 1 | ETA2022

Corticosteroids and mycophenolic acid have a synergistic effect on chemokines secretion in orbital cells from patients with graves’ ophthalmopathy

Martina Ferrari Silvia , Fallahi Poupak , Ragusa Francesca , Elia Giusy , Rosaria Paparo Sabrina , Patrizio Armando , Balestri Eugenia , Antonelli Alessandro

Objective: An enhancement of the response rate has been recently showed in patients with Graves’ ophthalmopathy (GO) treated with corticosteroids and mycophenolic acid. In GO, retro-orbital cells showed a cytokine-induced secretion of Th1 and Th2 chemokines. Since no data are present in literature about the effect of corticosteroids and mycophenolic acid on the chemokines secretion in GO orbital cells, we aim to deepen out this topic.Methods: We est...

ea0084ps2-07-64 | Graves’ Disease 1 | ETA2022

The effect of glucocorticoids on hyaluronan production of orbital fibroblasts

Galgoczi Erika , Katko Monika , Erdei Annamaria , Bodor Miklos , Ujhelyi Bernadett , Steiber Zita , Gyory Ferenc , V. Nagy Endre

Objectives: Glucocorticoids (GCs) are the first line therapy in moderate to severe, active thyroid eye disease (TED). While their beneficial immunosuppressive effects are well known, direct connective tissue effects are less characterized. The accumulation of extracellular matrix component hyaluronan (HA) and increased proliferation rate of fibroblasts are hallmarks connective tissue changes in TED. We examined the effect of methylprednisolone (MP), prednisolone (P), hydrocort...

ea0084ps2-07-65 | Graves’ Disease 1 | ETA2022

Hyperthyroidism in graves’ disease and subacute thyroiditis and association with cardiovascular events

Bajuk Studen Katica , Sesek Ana , Pirnat Edvard , Zaletel Katja , Gaberscek Simona

Objectives: Overt hyperthyroidism is reported to be associated with an increased mortality risk and an increased risk of cardiovascular (CV) complications such as an acute coronary syndrome requiring percutaneous coronary intervention, ischemic and non-ischemic stroke, atrial fibrillation and venous thromboembolism. Increased rate of acute CV events in the course of hyperthyroidism is well documented in Graves’ disease (GD) but not in subacute thyroiditis (ST). Last year ...

ea0084ps2-07-66 | Graves’ Disease 1 | ETA2022

Influence of thyroperoxydase and thyroglobulin antibodies on the presentation and the evolution of medically treated graves’ disease

Matei Constantinescu Stefan , Hospel Julien , Daumerie Chantal , Alexopoulou Orsalia , Maiter Dominique , Burlacu Maria-Cristina

Introduction: Thyrotropin receptor stimulating antibodies (TRAb) are responsible for Graves’ disease (GD) manifestations. Other thyroid antibodies, namely thyroperoxidase (TPOAb) and thyroglobulin (TGAb) antibodies are highly prevalent in GD, but their roles in GD presentation and evolution are controversial.Methods: We retrospectively analysed TPOAb and TGAb levels and evolution in 88 consecutive patients with newly diagnosed GD between 2000 and 20...